{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:46:24Z","timestamp":1765485984894},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T00:00:00Z","timestamp":1456444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s13402-016-0270-z","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T10:04:19Z","timestamp":1456481059000},"page":"253-263","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker"],"prefix":"10.1007","volume":"39","author":[{"given":"Renato Jos\u00e9","family":"Silva-Oliveira","sequence":"first","affiliation":[]},{"given":"Viviane Aline Oliveira","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Olga","family":"Martinho","sequence":"additional","affiliation":[]},{"given":"Adriana","family":"Cruvinel-Carloni","sequence":"additional","affiliation":[]},{"given":"Matias Eliseo","family":"Melendez","sequence":"additional","affiliation":[]},{"given":"Marcela Nunes","family":"Rosa","sequence":"additional","affiliation":[]},{"given":"Fl\u00e1via Escremim","family":"de Paula","sequence":"additional","affiliation":[]},{"given":"Luciano","family":"de Souza Viana","sequence":"additional","affiliation":[]},{"given":"Andr\u00e9 Lopes","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Rui Manuel","family":"Reis","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,2,26]]},"reference":[{"key":"270_CR1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","volume":"12","author":"Y Yarden","year":"2012","unstructured":"Y. Yarden, G. Pines, The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 12, 553\u2013563 (2012)","journal-title":"Nat. Rev. Cancer"},{"key":"270_CR2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/08977194.2014.952410","volume":"32","author":"SL Jeppe Knudsen","year":"2014","unstructured":"S.L. Jeppe Knudsen, A.S. Wai Mac, L. Henriksen, B. Deurs, L.M. Grovdal, EGFR signaling patterns are regulated by its different ligands. Growth Factors 32, 155\u2013163 (2014)","journal-title":"Growth Factors"},{"key":"270_CR3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-60761-795-2_7","volume":"661","author":"G Tarcic","year":"2010","unstructured":"G. Tarcic, Y. Yarden, MAP Kinase activation by receptor tyrosine kinases: in control of cell migration. Methods Mol. Biol. 661, 125\u2013135 (2010)","journal-title":"Methods Mol. Biol."},{"key":"270_CR4","doi-asserted-by":"crossref","unstructured":"S.B. Prasad, S.S. Yadav, M. Das, A. Modi, S. Kumari, L.K. Pandey, S. Singh, S. Pradhan, G. Narayan, PI3K\/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer. Cell. Oncol. 38, 215\u2013225 (2015)","DOI":"10.1007\/s13402-015-0224-x"},{"key":"270_CR5","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1073\/pnas.88.17.7792","volume":"88","author":"F Ciardiello","year":"1991","unstructured":"F. Ciardiello, N. Kim, T. Saeki, R. Dono, M.G. Persico, G.D. Plowman, J. Garrigues, S. Radke, G.J. Todaro, D.S. Salomon, Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc. Natl. Acad. Sci. U. S. A. 88, 7792\u20137796 (1991)","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"270_CR6","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","volume":"21","author":"FR Hirsch","year":"2003","unstructured":"F.R. Hirsch, M. Varella-Garcia, P.A. Bunn Jr., M.V. Di Maria, R. Veve, R.M. Bremmes, A.E. Baron, C. Zeng, W.A. Franklin, Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21, 3798\u20133807 (2003)","journal-title":"J. Clin. Oncol."},{"key":"270_CR7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/hed.21802","volume":"34","author":"L Sweeny","year":"2012","unstructured":"L. Sweeny, N.R. Dean, J.S. Magnuson, W.R. Carroll, E.E. Helman, S.O. Hyde, R.L. Desmond, E.L. Rosenthal, EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head Neck 34, 681\u2013686 (2012)","journal-title":"Head Neck"},{"key":"270_CR8","first-page":"1469","volume":"9","author":"ML Fjallskog","year":"2003","unstructured":"M.L. Fjallskog, M.H. Lejonklou, K.E. Oberg, B.K. Eriksson, E.T. Janson, Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin. Cancer Res. 9, 1469\u20131473 (2003)","journal-title":"Clin. Cancer Res."},{"key":"270_CR9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/path.2004","volume":"209","author":"JS Reis-Filho","year":"2006","unstructured":"J.S. Reis-Filho, C. Pinheiro, M.B. Lambros, F. Milanezi, S. Carvalho, K. Savage, P.T. Simpson, C. Jones, S. Swift, A. Mackay, R.M. Reis, J.L. Hornick, E.M. Pereira, F. Baltazar, C.D. Fletcher, A. Ashworth, S.R. Lakhani, F.C. Schmitt, EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J. Pathol. 209, 445\u2013453 (2006)","journal-title":"J. Pathol."},{"key":"270_CR10","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1158\/1078-0432.CCR-08-3210","volume":"15","author":"DA Bax","year":"2009","unstructured":"D.A. Bax, N. Gaspar, S.E. Little, L. Marshall, L. Perryman, M. Regairaz, M. Viana-Pereira, R. Vuononvirta, S.Y. Sharp, J.S. Reis-Filho, J.N. Stavale, S. Al-Sarraj, R.M. Reis, G. Vassal, A.D. Pearson, D. Hargrave, D.W. Ellison, P. Workman, C. Jones, EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin. Cancer Res. 15, 5753\u20135761 (2009)","journal-title":"Clin. Cancer Res."},{"key":"270_CR11","first-page":"913","volume":"28","author":"M Viana-Pereira","year":"2008","unstructured":"M. Viana-Pereira, J.M. Lopes, S. Little, F. Milanezi, D. Basto, F. Pardal, C. Jones, R.M. Reis, Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer Res. 28, 913\u2013920 (2008)","journal-title":"Anticancer Res."},{"key":"270_CR12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/bjc.2011.222","volume":"105","author":"K Iida","year":"2011","unstructured":"K. Iida, K. Nakayama, M.T. Rahman, M. Rahman, M. Ishikawa, A. Katagiri, S. Yeasmin, Y. Otsuki, H. Kobayashi, S. Nakayama, K. Miyazaki, EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. Br. J. Cancer 105, 420\u2013427 (2011)","journal-title":"Br. J. Cancer"},{"key":"270_CR13","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.cellsig.2007.06.023","volume":"19","author":"R Zandi","year":"2007","unstructured":"R. Zandi, A.B. Larsen, P. Andersen, M.T. Stockhausen, H.S. Poulsen, Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell. Signal. 19, 2013\u20132023 (2007)","journal-title":"Cell. Signal."},{"key":"270_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11523-013-0258-9","volume":"8","author":"K Kobayashi","year":"2013","unstructured":"K. Kobayashi, K. Hagiwara, Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target. Oncol. 8, 27\u201333 (2013)","journal-title":"Target. Oncol."},{"key":"270_CR15","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jocn.2008.12.005","volume":"16","author":"HK Gan","year":"2009","unstructured":"H.K. Gan, A.H. Kaye, R.B. Luwor, The EGFRvIII variant in glioblastoma multiforme. J. Clin. Neurosci. 16, 748\u2013754 (2009)","journal-title":"J. Clin. Neurosci."},{"key":"270_CR16","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1158\/0008-5472.CAN-13-1491","volume":"73","author":"BS Paugh","year":"2013","unstructured":"B.S. Paugh, X. Zhu, C. Qu, R. Endersby, A.K. Diaz, J. Zhang, D.A. Bax, D. Carvalho, R.M. Reis, A. Onar-Thomas, A. Broniscer, C. Wetmore, J. Zhang, C. Jones, D.W. Ellison, S.J. Baker, Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res. 73, 6219\u20136229 (2013)","journal-title":"Cancer Res."},{"key":"270_CR17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.oraloncology.2006.02.009","volume":"43","author":"K Laimer","year":"2007","unstructured":"K. Laimer, G. Spizzo, G. Gastl, P. Obrist, T. Brunhuber, D. Fong, V. Barbieri, S. Jank, W. Doppler, M. Rasse, B. Norer, High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol. 43, 193\u2013198 (2007)","journal-title":"Oral Oncol."},{"key":"270_CR18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/08977194.2014.896355","volume":"32","author":"AW Burgess","year":"2014","unstructured":"A.W. Burgess, Y.I. Henis, N.E. Hynes, T. Jovin, A. Levitzki, R. Pinkas-Kramarski, Y. Yarden, EGF receptor family: twisting targets for improved cancer therapies. Growth Factors 32, 74\u201381 (2014)","journal-title":"Growth Factors"},{"key":"270_CR19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.critrevonc.2011.11.010","volume":"83","author":"SH Ou","year":"2012","unstructured":"S.H. Ou, Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? a review of the clinical evidence. Crit. Rev. Oncol. Hematol. 83, 407\u2013421 (2012)","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"Suppl 1","key":"270_CR20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-200060001-00002","volume":"60","author":"E Raymond","year":"2000","unstructured":"E. Raymond, S. Faivre, J.P. Armand, Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 (Suppl 1), 15\u201323 (2000). discussion 41\u20132","journal-title":"Drugs"},{"key":"270_CR21","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2012.45.4272","volume":"31","author":"A Argiris","year":"2013","unstructured":"A. Argiris, M. Ghebremichael, J. Gilbert, J.W. Lee, K. Sachidanandam, J.M. Kolesar, B. Burtness, A.A. Forastiere, Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J. Clin. Oncol. 31, 1405\u20131414 (2013)","journal-title":"J. Clin. Oncol."},{"key":"270_CR22","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","volume":"73","author":"RT Dungo","year":"2013","unstructured":"R.T. Dungo, G.M. Keating, Afatinib: first global approval. Drugs 73, 1503\u20131515 (2013)","journal-title":"Drugs"},{"key":"270_CR23","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/1535-7163.MCT-12-1188","volume":"12","author":"SM Kim","year":"2013","unstructured":"S.M. Kim, M.R. Yun, Y.K. Hong, F. Solca, J.H. Kim, H.J. Kim, B.C. Cho, Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. Mol. Cancer Ther. 12, 2145\u20132156 (2013)","journal-title":"Mol. Cancer Ther."},{"key":"270_CR24","first-page":"383","volume":"5","author":"A Passaro","year":"2013","unstructured":"A. Passaro, B. Gori, F. de Marinis, Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials. J. Thorac. Dis. 5, 383\u2013384 (2013)","journal-title":"J. Thorac. Dis."},{"key":"270_CR25","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10549-012-2003-y","volume":"133","author":"NU Lin","year":"2012","unstructured":"N.U. Lin, E.P. Winer, D. Wheatley, L.A. Carey, S. Houston, D. Mendelson, P. Munster, L. Frakes, S. Kelly, A.A. Garcia, S. Cleator, M. Uttenreuther-Fischer, H. Jones, S. Wind, R. Vinisko, T. Hickish, A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res. Treat. 133, 1057\u20131065 (2012)","journal-title":"Breast Cancer Res. Treat."},{"key":"270_CR26","doi-asserted-by":"crossref","first-page":"e21487","DOI":"10.1371\/journal.pone.0021487","volume":"6","author":"H Xie","year":"2011","unstructured":"H. Xie, L. Lin, L. Tong, Y. Jiang, M. Zheng, Z. Chen, X. Jiang, X. Zhang, X. Ren, W. Qu, Y. Yang, H. Wan, Y. Chen, J. Zuo, H. Jiang, M. Geng, J. Ding, AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One 6, e21487 (2011)","journal-title":"PLoS One"},{"key":"270_CR27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1756-8722-7-22","volume":"7","author":"J Zhang","year":"2014","unstructured":"J. Zhang, J. Cao, J. Li, Y. Zhang, Z. Chen, W. Peng, S. Sun, N. Zhao, J. Wang, D. Zhong, X. Zhang, J. Zhang, A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. J. Hematol. Oncol. 7, 22 (2014)","journal-title":"J. Hematol. Oncol."},{"key":"270_CR28","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/jnci\/djp280","volume":"101","author":"S Siena","year":"2009","unstructured":"S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, A. Bardelli, Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl. Cancer Inst. 101, 1308\u20131324 (2009)","journal-title":"J. Natl. Cancer Inst."},{"key":"270_CR29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/JTO.0b013e3181fd83a4","volume":"6","author":"MS Tsao","year":"2011","unstructured":"M.S. Tsao, A. Sakurada, K. Ding, S. Aviel-Ronen, O. Ludkovski, N. Liu, A. Le Maitre, D. Gandara, D.H. Johnson, J.R. Rigas, L. Seymour, F.A. Shepherd, Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J. Thorac. Oncol. 6, 139\u2013147 (2011)","journal-title":"J. Thorac. Oncol."},{"key":"270_CR30","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1158\/1535-7163.MCT-09-1009","volume":"9","author":"K Takezawa","year":"2010","unstructured":"K. Takezawa, I. Okamoto, J. Tanizaki, K. Kuwata, H. Yamaguchi, M. Fukuoka, K. Nishio, K. Nakagawa, Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol. Cancer Ther. 9, 1647\u20131656 (2010)","journal-title":"Mol. Cancer Ther."},{"key":"270_CR31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","volume":"11","author":"W Roock De","year":"2010","unstructured":"W. De Roock, B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas, K.T. Kalogeras, V. Kotoula, D. Papamichael, P. Laurent-Puig, F. Penault-Llorca, P. Rougier, B. Vincenzi, D. Santini, G. Tonini, F. Cappuzzo, M. Frattini, F. Molinari, P. Saletti, S. De Dosso, M. Martini, A. Bardelli, S. Siena, A. Sartore-Bianchi, J. Tabernero, T. Macarulla, F. Di Fiore, A.O. Gangloff, F. Ciardiello, P. Pfeiffer, C. Qvortrup, T.P. Hansen, E. Van Cutsem, H. Piessevaux, D. Lambrechts, M. Delorenzi, S. Tejpar, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753\u2013762 (2010)","journal-title":"Lancet Oncol."},{"key":"270_CR32","doi-asserted-by":"crossref","first-page":"e65995","DOI":"10.1371\/journal.pone.0065995","volume":"8","author":"ZX Yuan","year":"2013","unstructured":"Z.X. Yuan, X.Y. Wang, Q.Y. Qin, D.F. Chen, Q.H. Zhong, L. Wang, J.P. Wang, The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One 8, e65995 (2013)","journal-title":"PLoS One"},{"key":"270_CR33","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1158\/1535-7163.MCT-12-0311","volume":"11","author":"SM Kim","year":"2012","unstructured":"S.M. Kim, O.J. Kwon, Y.K. Hong, J.H. Kim, F. Solca, S.J. Ha, R.A. Soo, J.G. Christensen, J.H. Lee, B.C. Cho, Activation of IL-6R\/JAK1\/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol. Cancer Ther. 11, 2254\u20132264 (2012)","journal-title":"Mol. Cancer Ther."},{"key":"270_CR34","doi-asserted-by":"crossref","first-page":"e33585","DOI":"10.1371\/journal.pone.0033585","volume":"7","author":"LB Cardeal","year":"2012","unstructured":"L.B. Cardeal, E. Boccardo, L. Termini, T. Rabachini, M.A. Andreoli, C. di Loreto, A. Longatto Filho, L.L. Villa, S.S. Maria-Engler, HPV16 oncoproteins induce MMPs\/RECK-TIMP-2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis. PLoS One 7, e33585 (2012)","journal-title":"PLoS One"},{"key":"270_CR35","doi-asserted-by":"crossref","first-page":"e50043","DOI":"10.1371\/journal.pone.0050043","volume":"7","author":"V Kannen","year":"2012","unstructured":"V. Kannen, H. Hintzsche, D.L. Zanette, W.A. Silva Jr., S.B. Garcia, A.M. Waaga-Gasser, H. Stopper, Antiproliferative effects of fluoxetine on colon cancer cells and in a colonic carcinogen mouse model. PLoS One 7, e50043 (2012)","journal-title":"PLoS One"},{"key":"270_CR36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1158\/0008-5472.CAN-09-2189","volume":"70","author":"BM Costa","year":"2010","unstructured":"B.M. Costa, J.S. Smith, Y. Chen, J. Chen, H.S. Phillips, K.D. Aldape, G. Zardo, J. Nigro, C.D. James, J. Fridlyand, R.M. Reis, J.F. Costello, Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res. 70, 453\u2013462 (2010)","journal-title":"Cancer Res."},{"key":"270_CR37","doi-asserted-by":"crossref","first-page":"e5209","DOI":"10.1371\/journal.pone.0005209","volume":"4","author":"DA Bax","year":"2009","unstructured":"D.A. Bax, S.E. Little, N. Gaspar, L. Perryman, L. Marshall, M. Viana-Pereira, T.A. Jones, R.D. Williams, A. Grigoriadis, G. Vassal, P. Workman, D. Sheer, R.M. Reis, A.D. Pearson, D. Hargrave, C. Jones, Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. PLoS One 4, e5209 (2009)","journal-title":"PLoS One"},{"key":"270_CR38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.2910610117","volume":"61","author":"M Cardinali","year":"1995","unstructured":"M. Cardinali, H. Pietraszkiewicz, J.F. Ensley, K.C. Robbins, Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. Int. J. Cancer 61, 98\u2013103 (1995)","journal-title":"Int. J. Cancer"},{"key":"270_CR39","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1593\/neo.91110","volume":"11","author":"MF Calmon","year":"2009","unstructured":"M.F. Calmon, R.V. Rodrigues, C.M. Kaneto, R.P. Moura, S.D. Silva, L.D. Mota, D.G. Pinheiro, C. Torres, A.F. de Carvalho, P.M. Cury, F.D. Nunes, I.N. Nishimoto, F.A. Soares, A.M. da Silva, L.P. Kowalski, H. Brentani, C.F. Zanelli, W.A. Silva Jr., P. Rahal, E.H. Tajara, D.M. Carraro, A.A. Camargo, S.R. Valentini, Epigenetic silencing of CRABP2 and MX1 in head and neck tumors. Neoplasia 11, 1329\u20131339 (2009)","journal-title":"Neoplasia"},{"key":"270_CR40","doi-asserted-by":"crossref","first-page":"e20584","DOI":"10.1371\/journal.pone.0020584","volume":"6","author":"PT Hennessey","year":"2011","unstructured":"P.T. Hennessey, M.F. Ochs, W.W. Mydlarz, W. Hsueh, L. Cope, W. Yu, J.A. Califano, Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS One 6, e20584 (2011)","journal-title":"PLoS One"},{"key":"270_CR41","doi-asserted-by":"crossref","first-page":"e13510","DOI":"10.1371\/journal.pone.0013510","volume":"5","author":"JF Sousa","year":"2010","unstructured":"J.F. Sousa, R. Torrieri, R.R. Silva, C.G. Pereira, V. Valente, E. Torrieri, K.C. Peronni, W. Martins, N. Muto, G. Francisco, C.A. Brohem, C.G. Carlotti Jr., S.S. Maria-Engler, R. Chammas, E.M. Espreafico, Novel primate-specific genes, RMEL 1, 2 and 3, with highly restricted expression in melanoma, assessed by new data mining tool. PLoS One 5, e13510 (2010)","journal-title":"PLoS One"},{"key":"270_CR42","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/mc.22222","volume":"54","author":"J Afonso","year":"2015","unstructured":"J. Afonso, L.L. Santos, V. Miranda-Goncalves, A. Morais, T. Amaro, A. Longatto-Filho, F. Baltazar, CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance. Mol. Carcinog. 54, 1451\u20131466 (2015)","journal-title":"Mol. Carcinog."},{"key":"270_CR43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/ERC-13-0132","volume":"21","author":"F Morais-Santos","year":"2014","unstructured":"F. Morais-Santos, V. Miranda-Goncalves, S. Pinheiro, A.F. Vieira, J. Paredes, F.C. Schmitt, F. Baltazar, C. Pinheiro, Differential sensitivities to lactate transport inhibitors of breast cancer cell lines. Endocr. Relat. Cancer. 21, 27\u201338 (2014)","journal-title":"Endocr. Relat. Cancer."},{"key":"270_CR44","doi-asserted-by":"crossref","first-page":"e59104","DOI":"10.1371\/journal.pone.0059104","volume":"8","author":"O Martinho","year":"2013","unstructured":"O. Martinho, F. Pinto, S. Granja, V. Miranda-Goncalves, M.A. Moreira, L.F. Ribeiro, C. di Loreto, M.R. Rosner, A. Longatto-Filho, R.M. Reis, RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy. PLoS One 8, e59104 (2013)","journal-title":"PLoS One"},{"key":"270_CR45","doi-asserted-by":"crossref","unstructured":"V. Silva, M. Rosa, A. Tansini, J. Lima, C. Jones, L. Pianowski, R. Reis, Cytotoxic activity of semi-synthetic ingenol derived from Euphorbia tirucalli on a large panel of human cancer cell lines. J. Clin. Oncol. 31, (2013)","DOI":"10.1200\/jco.2013.31.15_suppl.e13559"},{"key":"270_CR46","doi-asserted-by":"crossref","unstructured":"R.M. Reis, V.A.O. Silva, M.N. Rosa, A. Tansini, J.P.D.S.N. Lima, P.L.F.C. Jones, Cytotoxic effect of euphol from Euphorbia tirucalli on a large panel of human. cancer cell lines. J. Clin. Oncol. 31, abstract (2013)","DOI":"10.1200\/jco.2013.31.15_suppl.e13557"},{"key":"270_CR47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1593\/tlo.12400","volume":"6","author":"O Martinho","year":"2013","unstructured":"O. Martinho, R. Silva-Oliveira, V. Miranda-Goncalves, C. Clara, J.R. Almeida, A.L. Carvalho, J.T. Barata, R.M. Reis, In vitro and in vivo analysis of RTK inhibitor efficacy and identification of its novel targets in glioblastomas. Transl. Oncol. 6, 187\u2013196 (2013)","journal-title":"Transl. Oncol."},{"key":"270_CR48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"R.H. Shoemaker, The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813\u2013823 (2006)","journal-title":"Nat. Rev. Cancer"},{"key":"270_CR49","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-14-0421","volume":"20","author":"F Pinto","year":"2014","unstructured":"F. Pinto, N. Pertega-Gomes, M.S. Pereira, J.R. Vizcaino, P. Monteiro, R.M. Henrique, F. Baltazar, R.P. Andrade, R.M. Reis, T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. Clin. Cancer Res. 20, 4949\u20134961 (2014)","journal-title":"Clin. Cancer Res."},{"key":"270_CR50","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.bjc.6605381","volume":"101","author":"GE Konecny","year":"2009","unstructured":"G.E. Konecny, R. Glas, J. Dering, K. Manivong, J. Qi, R.S. Finn, G.R. Yang, K.L. Hong, C. Ginther, B. Winterhoff, G. Gao, J. Brugge, D.J. Slamon, Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br. J. Cancer 101, 1699\u20131708 (2009)","journal-title":"Br. J. Cancer"},{"key":"270_CR51","doi-asserted-by":"crossref","unstructured":"L.S. Yamane, C. Scapulatempo-Neto, L. Alvarenga, C.Z. Oliveira, G.N. Berardinelli, E. Almodova, T.R. Cunha, G. Fava, W. Colaiacovo, A. Melani, J.H. Fregnani, R.M. Reis, D.P. Guimaraes, KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy. Oncol. Rep. 32, 1419\u20131426 (2014)","DOI":"10.3892\/or.2014.3338"},{"key":"270_CR52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2559.2009.03323.x","volume":"55","author":"O Martinho","year":"2009","unstructured":"O. Martinho, A. Gouveia, M. Viana-Pereira, P. Silva, A. Pimenta, R.M. Reis, J.M. Lopes, Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. Histopathology 55, 53\u201362 (2009)","journal-title":"Histopathology"},{"key":"270_CR53","unstructured":"The Roche Cancer Genome Database, 2014 [cited 2014; Available from: http:\/\/rcgdb.bioinf.uni-sb.de\/MutomeWeb\/ (2014)"},{"key":"270_CR54","first-page":"103","volume":"22","author":"WG Dirks","year":"2005","unstructured":"W.G. Dirks, S. Faehnrich, I.A. Estella, H.G. Drexler, Short tandem repeat DNA typing provides an international reference standard for authentication of human cell lines. ALTEX 22, 103\u2013109 (2005)","journal-title":"ALTEX"},{"key":"270_CR55","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1476-4598-7-92","volume":"7","author":"M Monticone","year":"2008","unstructured":"M. Monticone, E. Biollo, M. Maffei, A. Donadini, F. Romeo, C.T. Storlazzi, W. Giaretti, P. Castagnola, Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. Mol. Cancer 7, 92 (2008)","journal-title":"Mol. Cancer"},{"key":"270_CR56","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","volume":"27","author":"D Li","year":"2008","unstructured":"D. Li, L. Ambrogio, T. Shimamura, S. Kubo, M. Takahashi, L.R. Chirieac, R.F. Padera, G.I. Shapiro, A. Baum, F. Himmelsbach, W.J. Rettig, M. Meyerson, F. Solca, H. Greulich, K.K. Wong, BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27, 4702\u20134711 (2008)","journal-title":"Oncogene"},{"key":"270_CR57","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","volume":"66","author":"A Lievre","year":"2006","unstructured":"A. Lievre, J.B. Bachet, D. Le Corre, V. Boige, B. Landi, J.F. Emile, J.F. Cote, G. Tomasic, C. Penna, M. Ducreux, P. Rougier, F. Penault-Llorca, P. Laurent-Puig, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992\u20133995 (2006)","journal-title":"Cancer Res."},{"key":"270_CR58","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Y. Pylayeva-Gupta, E. Grabocka, D. Bar-Sagi, RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761\u2013774 (2011)","journal-title":"Nat. Rev. Cancer"},{"key":"270_CR59","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2012.43.0454","volume":"31","author":"PJ Roberts","year":"2013","unstructured":"P.J. Roberts, T.E. Stinchcombe, KRAS mutation: should we test for it, and does it matter? J. Clin. Oncol. 31, 1112\u20131121 (2013)","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"270_CR60","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","volume":"28","author":"AF Gazdar","year":"2009","unstructured":"A.F. Gazdar, Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28(Suppl 1), S24\u201331 (2009)","journal-title":"Oncogene"},{"key":"270_CR61","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, D.A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129\u20132139 (2004)","journal-title":"N. Engl. J. Med."},{"key":"270_CR62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","volume":"16","author":"JC Yang","year":"2015","unstructured":"J.C. Yang, Y.L. Wu, M. Schuler, M. Sebastian, S. Popat, N. Yamamoto, C. Zhou, C.P. Hu, K. O'Byrne, J. Feng, S. Lu, Y. Huang, S.L. Geater, K.Y. Lee, C.M. Tsai, V. Gorbunova, V. Hirsh, J. Bennouna, S. Orlov, T. Mok, M. Boyer, W.C. Su, K.H. Lee, T. Kato, D. Massey, M. Shahidi, V. Zazulina, L.V. Sequist, Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 16, 141\u2013151 (2015)","journal-title":"Lancet Oncol."},{"key":"270_CR63","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1158\/0008-5472.CAN-06-4625","volume":"67","author":"N Godin-Heymann","year":"2007","unstructured":"N. Godin-Heymann, I. Bryant, M.N. Rivera, L. Ulkus, D.W. Bell, D.J. Riese 2nd, J. Settleman, D.A. Haber, Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res. 67, 7319\u20137326 (2007)","journal-title":"Cancer Res."},{"key":"270_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13402-015-0221-0","volume":"38","author":"S Derks","year":"2015","unstructured":"S. Derks, B. Diosdado, Personalized cancer medicine: next steps in the genomic era. Cell Oncol. 38, 1\u20132 (2015)","journal-title":"Cell Oncol"},{"key":"270_CR65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s13402-014-0192-6","volume":"38","author":"L Prudkin","year":"2015","unstructured":"L. Prudkin, P. Nuciforo, Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic. Cell Oncol. 38, 39\u201348 (2015)","journal-title":"Cell Oncol"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-016-0270-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13402-016-0270-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-016-0270-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T03:51:05Z","timestamp":1600228265000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13402-016-0270-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,26]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1007\/s13402-016-0270-z","relation":{},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,26]]}}}